'Breakthrough' tag puts Roche's Alecensa in line for ALK-market battle with Pfizer

roche building

Last month, Novartis put up data supporting a first-line nod for its med for ALK+ non-small cell lung cancer, Zykadia. But this week? It’s Roche’s contender that’s zooming ahead.

Monday, Roche’s Alecensa picked up a breakthrough therapy designation from the FDA in patients who haven’t yet been treated with ALK-inhibitor drugs. That puts the drug on track for a speedy trip down toward approval. It’s the second breakthrough nod for Alecensa, which launched last December as a treatment for patients who'd failed on Pfizer’s targeted med Xalkori.

This new use in previously untreated patients would help Alecensa take on its Pfizer rival, which racked up $488 million in sales last year with the first-line setting all to itself. Roche would like to snag a piece of the market, to build on Alecensa's current sales of $74 million through the first half of this year.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Roche isn’t the only one eyeing a piece of Xalkori’s market, though. Fellow Swiss giant Novartis' player in the mix, Zykadia, recently topped standard chemo at improving progression-free survival in previously untreated patients.

In addition to the breakthrough tag, though, Roche may have a leg up on its crosstown rival when it comes to trial design. "It's better to design something against the standard of care," Bank Vontobel analyst Stefan Schneider has told Reuters, criticizing the Novartis trial setup that pitted Zykadia against chemo. "Taken from the current data, we assume that Alecensa will be superior to Zykadia from an efficacy and safety perspective in the first line ALK+ non-small cell lung cancer."

Alecensa is already beating out Zykadia in the sales race, too; Novartis’ entrant generated $48 million in the first half of 2016.

- read the release

Related Articles:
Novartis' new Zykadia data put first-line nod in sight, but a Roche showdown looms
Roche challenges hometown rival Novartis with new targeted lung-cancer med Alecensa
Novartis grabs Zykadia approval in Europe, setting the stage for showdown
Pfizer nabs speedy FDA review for new use of lung cancer med Xalkori

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.